Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian C Shaffer

Showing results (1-10 of 79) with videos related to

Pageof 8
Sort By:
Haematologica|November 13, 2025
The ABCs of donor selection: availability before compatibility?Brian C Shaffer, Miguel Angel Perales
Seminars in Hematology|December 1, 2020
Selection of allogeneic hematopoietic cell transplant donors to optimize natural killer cell alloreactivityBrian C Shaffer, Katharine C Hsu
Current Opinion in Immunology|April 30, 2026
Optimal donor selection for transplant to reduce GVHD risk and augment graft-versus-malignancy efficacyBrian C Shaffer, Bronwen E Shaw
Best Practice & Research. Clinical Haematology|November 29, 2016
How important is NK alloreactivity and KIR in allogeneic transplantation?Brian C Shaffer, Katharine C Hsu
Blood|February 26, 2026
How I Treat: Selection of Hematopoietic Cell Donors in the Era of Post-Transplant CyclophosphamideBrian C Shaffer, Stephanie J Lee, Miguel-Angel Perales
Bone Marrow Transplantation|November 20, 2024
Measurable residual disease testing and allogeneic hematopoietic cell transplantation for AML: adapting Pre-MEASURE to clinical practiceBrian C Shaffer, Partow Kebriaei, Marcos de Lima, et al.
Transplantation and Cellular Therapy|January 6, 2026
Response to "Revisiting Allogeneic Hematopoietic Cell Donor Selection Guidelines: Umbilical Cord Blood in the PTCy Era"Brian C Shaffer, Stephen R Spellman, Browen E Shaw, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|March 14, 2012
Drug resistance: still a daunting challenge to the successful treatment of AMLBrian C Shaffer, Jean-Pierre Gillet, Chirayu Patel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 17, 2016
Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell TransplantationBrian C Shaffer, Jean-Benoit Le Luduec, Christopher Forlenza, et al.
Blood Advances|April 21, 2023
Association between non-European ancestry, low socioeconomic status, and receipt of HLA-disparate allografts in adult BMT recipientsWarren B Fingrut, Stephanie Chinapen, Jessica Flynn, et al.
Pageof 8

Showing results (1-10 of 79) with videos related to

Sort By:
Pageof 8
Haematologica|November 13, 2025
The ABCs of donor selection: availability before compatibility?Brian C Shaffer, Miguel Angel Perales
Seminars in Hematology|December 1, 2020
Selection of allogeneic hematopoietic cell transplant donors to optimize natural killer cell alloreactivityBrian C Shaffer, Katharine C Hsu
Current Opinion in Immunology|April 30, 2026
Optimal donor selection for transplant to reduce GVHD risk and augment graft-versus-malignancy efficacyBrian C Shaffer, Bronwen E Shaw
Best Practice & Research. Clinical Haematology|November 29, 2016
How important is NK alloreactivity and KIR in allogeneic transplantation?Brian C Shaffer, Katharine C Hsu
Blood|February 26, 2026
How I Treat: Selection of Hematopoietic Cell Donors in the Era of Post-Transplant CyclophosphamideBrian C Shaffer, Stephanie J Lee, Miguel-Angel Perales
Bone Marrow Transplantation|November 20, 2024
Measurable residual disease testing and allogeneic hematopoietic cell transplantation for AML: adapting Pre-MEASURE to clinical practiceBrian C Shaffer, Partow Kebriaei, Marcos de Lima, et al.
Transplantation and Cellular Therapy|January 6, 2026
Response to "Revisiting Allogeneic Hematopoietic Cell Donor Selection Guidelines: Umbilical Cord Blood in the PTCy Era"Brian C Shaffer, Stephen R Spellman, Browen E Shaw, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|March 14, 2012
Drug resistance: still a daunting challenge to the successful treatment of AMLBrian C Shaffer, Jean-Pierre Gillet, Chirayu Patel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 17, 2016
Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell TransplantationBrian C Shaffer, Jean-Benoit Le Luduec, Christopher Forlenza, et al.
Blood Advances|April 21, 2023
Association between non-European ancestry, low socioeconomic status, and receipt of HLA-disparate allografts in adult BMT recipientsWarren B Fingrut, Stephanie Chinapen, Jessica Flynn, et al.
Pageof 8